Low incidence of acute rejection in hepatitis B virus positive liver transplant recipients and the impact of hepatitis B immunoglobulin

Veerappan, Annapoorani; VanWagner, Lisa B.; Mathew, James M.; Huang, Xuemei; Miller, Joshua; Lapin, Brittany; Levitsky, Josh

doi:10.1016/j.humimm.2016.02.009

Cited by 5 publications

(6 citation statements)

References 25 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are limited in vitro data suggesting that HBIg may inhibit alloantigen specific T cell responses, dendritic cell maturation, and cytokine production [ 35 ]. A recent study [ 37 ], albeit with lower HBIg concentrations as in prior in vitro studies [ 38 , 39 ], found no enhancing role on regulatory T cell generation. However, more in vivo and in vitro data are needed to determine the possible immunosuppressive effect of HBIg.…”

Section: Discussionmentioning

confidence: 88%

Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis

et al. 2018

View full text Add to dashboard Cite

BackgroundLong-term real-world data are relatively sparse regarding recurrence of chronic hepatitis B virus (HBV) infection after liver transplantation using hepatitis B immunoglobulin (HBIg) and nucleos(t)ide analogue (NUC) prophylaxis.Material/MethodsData from 371 adults transplanted for HBV-related disease at 20 European centers and given HBIg for ≥12 months ± NUC therapy were analyzed retrospectively.ResultsHBIg comprised Hepatect® (iv HBIgB; n=299), subcutaneous Zutectra® (sc HBIg, n=236), and other HBIg preparations (n=130); 93.5% received NUC therapy. Mean follow-up was 6.8±3.5 years. The primary efficacy variable, freedom from HBV recurrence, occurred in 95.7% of patients (95% CI [93.1%, 97.5%]). The observed incidence of recurrence was 16/371 (4.3%) (annual rate 0.65%); 5/16 patients with recurrence had discontinued HBIg and 7/16 had anti-HBs <100 IU/l. Excluding these 7 patients, the HBV recurrence rate was 2.4%. The recurrence rate while on HBIg therapy was 1 per 2069 months. In patients who discontinued HBIg, risk of HBV recurrence versus sc HBIg users was increased by 5.2-fold (1 per 1 603 versus 1 per 8379 treatment months). The annual rate of HBV-related hepatocellular carcinoma (HCC) recurrence was 1.7%.ConclusionsThese results support the long-term use of HBIg with NUC therapy as an effective management strategy to minimize risk of HBV recurrence and virus-related complications after liver transplantation.

show abstract

Section: Discussionmentioning

confidence: 88%

Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Cell tracking dyes are commonly combined with each other, with fluorescent antibodies, and/or with genetic markers to enable: (a) in vitro or in vivo tracking of phenotypically defined subsets within heterogeneous populations (e.g., [5,22]); or (b) identification and characterization of cell populations that do or do not proliferate in response to a given stimulus (e.g., [8,18,37]). The multiplicity of spectral detection options available on most digital flow cytometers means that when selecting fluorochrome combinations for such studies it is important to evaluate the impact of candidate cell tracking dye(s) on the ability to simultaneously detect other common fluorochromes.…”

Section: Methodsmentioning

confidence: 99%

“…Both dye types have also proven valuable for a wide range of in vitro studies including antigen presentation [12–14], mechanism and specificity of cytotoxic effector killing [15–17] (Subheading 3.6), and regulatory T cell activity [18,19]. Infectious agents [20,21], subcellular components ( e.g.…”

Section: Introductionmentioning

confidence: 99%

“…Monitoring the proliferative status of stem/progenitor and immune cells is among the most common applications of both classes of cell tracking dyes [1,2,18,19,27,30,31], due to the significant limitations associated with alternative methods. Using dye dilution to assess extent of cell division avoids safety and regulatory issues associated with tritiated thymidine incorporation, which is ill-suited for single cell analysis of mixed populations, detects only cells actively synthesizing DNA during the pulse, and doesn’t allow isolation of daughter cells for follow-on analyses (e.g., immunophenotyping, gene expression, proteomics, or functional assays).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Monitoring Cell Proliferation by Dye Dilution: Considerations for Probe Selection

Tario

Conway

Muirhead³

et al. 2017

Methods in Molecular Biology

View full text Add to dashboard Cite

In the third edition of this series, we described protocols for labeling cell populations with tracking dyes, and addressed issues to be considered when combining two different tracking dyes with other phenotypic and viability probes for the assessment of cytotoxic effector activity and regulatory T cell functions. We summarized key characteristics of and differences between general protein and membrane labeling dyes, discussed determination of optimal staining concentrations, and provided detailed labeling protocols for both dye types. Examples of the advantages of two color cell tracking were provided in the form of protocols for: (a) independent enumeration of viable effector and target cells in a direct cytotoxicity assay; and (b) an in vitro suppression assay for simultaneous proliferation monitoring of effector and regulatory T cells. The number of commercially available fluorescent cell tracking dyes has expanded significantly since the last edition, with new suppliers and/or new spectral properties being added at least annually. In this fourth edition, we describe evaluations to be performed by the supplier and/or user when characterizing a new cell tracking dye and by the user when selecting one for use in multicolor proliferation monitoring. These include methods for: Assessment of the dye’s spectral profile on the laboratory’s flow cytometer(s) to optimize compatibility with other employed fluorochromes and minimize compensation problems;Evaluating the effect of labeling on cell growth rate;Testing the fidelity with which dye dilution reports cell division;Determining the maximum number of generations to be included when using dye dilution profiles to estimate fold population expansion or frequency of responder cells; andVerifying that relevant cell functions (e.g., effector activity) remain unaltered by tracking dye labeling.

show abstract

“…Zhao i saradnici iznose zaključak da je transplantacija jetre definitivan terapeutski izbor, dok nukleozidni analozi mogu poboljšati preživljavanje kod nekih bolesnika (23). Preporuka o primeni humanog B imunoglobulina vremenom je, takođe, promenjena i suspendovana (24,25). Postoje i studije koje navode uspešnost terapijske izmene plazme u preživljavanju ovih pacijenata (26).…”

Section: Diskusijaunclassified

Fulminant hepatitis B: A case report

Pavić¹,

Maričić²,

Vujović³

et al. 2021

Med gl Spec bol štit Zlatibor

View full text Add to dashboard Cite

Introduction: Fulminant hepatitis is a severe acute liver disease. It occurs due to massive necrosis of hepatocytes. The disease progresses to lethal outcome within a few days. The most common causes of this disease are toxic substances, autoimmune and viral hepatitis. The aim of the study was to present a lethal case of fulminant hepatitis caused by hepatitis B virus in a patient with treated bladder cancer. Case Outline: A 63-year-old patient was admitted for treatment due to weakness, nausea and decreased diuresis. She had surgery to remove her bladder, which was affected by a malignant process, two years earlier. On admission, she had a subicteric, orderly auscultatory finding. The abdomen was palpably painful below the right costal arch, without organomegaly. The ureterostomy was functional. The diagnosis of acute HBV infection was made by evidence of HBsAg, HBeAg and antiHBc IgM antibody titer. Laboratory findings indicated an increase in transaminases, urea, creatinine, total and conjugated bilirubin, decreased albumin values and coagulation disorders. The patient was treated with hepatoprotective therapy, antibiotics and antiviral therapy. Hemodialysis was performed as needed. Encephalopathy developed on the third day with further progression.The disease progressed with gastrointestinal bleeding and cardiac disorders and ended in death on the ninth day. Conclusion: Fulminant liver damage caused by hepatitis B virus is a severe disease that can be complicated by acute renal failure. The prognosis of the disease is often unfavorable, so optimal treatment requires a liver transplant.

show abstract

Low incidence of acute rejection in hepatitis B virus positive liver transplant recipients and the impact of hepatitis B immunoglobulin

Cited by 5 publications

References 25 publications

Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis

Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis

Monitoring Cell Proliferation by Dye Dilution: Considerations for Probe Selection

Fulminant hepatitis B: A case report

Contact Info

Product

Resources

About